CD274 and cancer: Nevertheless, the reduced G(R) CIC subtype (Fig. 3G) observed upon anti‐PD‐L1 antibody treatment, mainly used in MSI‐H CRC patients, may potentially improve the cancer immunotherapy by promoting the accessibility of inner cancer cells for NK cells and cytotoxic T cells.